Combination immunotherapy induces post-intervention control of HIV. (PubMed, Res Sq) - Apr 1, 2025 - "Here, we performed a single-arm, proof-of-concept combination study of these three approaches in ten people with HIV on ART that included (1) therapeutic vaccination with an HIV/Gag conserved element (CE)-targeted DNA+IL-12 prime/MVA boost regimen followed by (2) administration of two bNAbs (10-1074 and VRC07-523LS) and a toll-like receptor 9 (TLR9) agonist (lefitolimod) during ART suppression, followed by (3) repeat bNAb administration at the time of ART interruption. Robust expansion of activated CD8+ T cells early in response to rebounding virus correlated with lower viral load set points. These data suggest that combination immunotherapy approaches might prove effective to induce sustained control of HIV by slowing rebound and improving CD8+ T cell responses, and that these approaches should continue to be optimized."
Journal • Human Immunodeficiency Virus • Infectious Disease • CD8 • IL12A
|
|
Amelia Deitchman; Barbara Felber; Christos Petropoulos; David Glidden; Demi Sandel; Devi SenGupta; Elena Vendrame; George Pavlakis; Gina Borgo; Hari Tummala; Jacqueline Reeves; James Mullins; Jennifer Tisoncik-Go; Kara Chew; Kathleen Schwartz; Leanne Whitmore; Leonid Serebryannyy; Lillian Cohn; Lily Zemelko; Lucio Gama; Mandana Khalili; Marina Caskey; Matthew Spitzer; Meghann Williams; Michael Gale; Michael Peluso; Michel Nussenzweig; Michiko Shimoda; Monika Deswal; Rachel Rutishauser; Rafael Tibúrcio; Rebecca Hoh; Richard Koup; Sandeep Narpala; Shayleen Singh; Steven Deeks; Steven Yukl; Sun Jin Kim; Thomas Dalhuisen; Timothy Henrich
|